Neoadjuvant Letrozole and Lapatinib in Postmenopausal Women With ER and Her2 Positive Breast Cancer.

Trial Profile

Neoadjuvant Letrozole and Lapatinib in Postmenopausal Women With ER and Her2 Positive Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Lapatinib (Primary) ; Letrozole (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms Neo-All-In
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 11 Oct 2016 Results of explorative mutational analysis (n=21) presented at the 41st European Society for Medical Oncology Congress.
    • 19 Nov 2013 Planned end date changed from 1 Apr 2013 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top